China Microarray Market (2026-2036)
The China Microarray Market was valued at $569.0 million in 2025. This market is expected to reach $1,621.9 million by 2036 from an estimated $622.5 million in 2026, at a CAGR of 10.0% during the forecast period from 2026 to 2036. China Microarray Market Size & Forecast The growth of the China microarray
- Published
- Sep 2026
- Pages
- 109
- Format
- PDF + Excel
- Report ID
- MR-1321
- Base year
- 2023
- 2025 · FORECAST
- $569.0M
- 2031
- $1.01B
- CAGR 2024–2031
- 10.0%
2023 baseline · 2024–2031 forecast at 10.0% CAGR · hover a bar for the value
Key highlights
The Consumables Segment to Account for the Largest Share of this Market in 2024
The Drug Discovery & Development Segment to Account for the Largest Share of this Market in 2024
The Pharmaceutical and Biotechnology Companies Segment to Account for the Largest Share of this Market in 2024
Report summary
| Particulars | Details |
|---|---|
| Page No | 109 |
| Format | |
| Forecast Period | 2024-2031 |
| Base Year | 2023 |
| CAGR | 8.4% |
| Market Size (Value) | $910.4 million by 2031 |
| Segments Covered | By Product · Consumables · Kits · DNA & RNA Microarray Kits · cDNA Microarray Kits · Oligo Microarray Kits · Other DNA & RNA Microarray Kits · (Other DNA & RNA microarray kits comprise of RNA microarrays, SNP microarrays, and BAC microarrays) · Protein Microarray Kits · Tissue Microarray Kits · Other Microarray Kits · (Other microarray kits comprise cell microarrays, ChIP-chip microarrays (Chromatin Immunoprecipitation Microarrays), and glycan microarrays) · Other Consumables · (Other consumables comprise buffers, reagents, slides, well plates, coated slides, and microtiter plates) · Instruments · Software · Services · By Application · Drug Discovery & Development · Research Applications · Diagnostics · Other Applications · (Other applications comprise agriculture, food & beverage, and forensics) · By End User · Pharmaceutical and Biotechnology Companies · Contract Research Organizations (CROs) · Research & Academic Institutes · Hospitals & Diagnostic Laboratories · Other End Users · (Other end users comprise veterinary clinics, agricultural industry, and forensic laboratories) |
| Countries Covered | China |
| Key Companies | Sino Biological, Inc. (China), CapitalBio Technology Co., Ltd. (China), Arrayit Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), and Qiagen N.V. (Netherlands), and RayBiotech Life, Inc. (U.S.) |
Report overview
Segments covered: product, application.
The growth of the China microarray market is driven by expanding research applications of microarrays, increasing genomics and proteomics research, the rising prevalence of cancers and genetic disorders, and increasing R&D investments by the pharma and biotech stakeholders. However, the market growth is restrained by the expensive nature of microarrays over other genetic testing approaches and the increasing adoption of next-generation sequencing technologies. Moreover, the growing adoption of personalized medicines is expected to generate growth opportunities for market stakeholders. The low sensitivity and correctness of microarrays pose a challenge to the growth of the market.
Market dynamics
6 factors across 3 forcesIncreasing Research Applications of Microarrays
Microarray technology involves the binding of an array of millions of nucleic acid fragments to a solid surface, which is generally referred to as a chip. A DNA or RNA sample is then added to the chip in order to initiate complementary base pairing when the immobilized fragments on the chip produce light through fluorescence that is detected using a specialized device. Microarray technology allows genomic analysis without sequencing and greatly reduces the cost of performing experiments across the fields of biology and biomedicine. Initially, microarray technology was only used to measure gene expression or quantify certain small molecules. However, the advancements in microarray technology are making it a fast and reliable solution for various applications, such as biomarkers and drug discovery.
Research applications of microarray include clinical trials and drug discoveries for various purposes, such as gene expression, detection of DNA sequences, studying gene mutations, and the presence of certain biomarkers. It can be used as a genomic tool to study and compare different features of the genome based on different diseases and conditions. Due to the study of genomics and data acquired using the technology, population-based studies can also be carried out.
Rising Prevalence of Cancers and Genetic Disorders
Cancer is a major cause of death and a prominent obstacle to improving life expectancy around the world. According to GLOBOCAN, in China, the number of new cancer cases in 2022 was 4.8 million, which is expected to reach 7.1 million by 2045. Thus, the increasing number of cancer cases is expected to boost the adoption of microarrays in clinical settings. Microarray applications in oncology research range from basic drug discovery and translational research to patient testing, clinical trials, and population studies.
Apart from cancer, China also shares a significant burden of rare genetic disorders across the world. Congenital disabilities in children have been a major factor contributing to the country’s disease burden. The government currently subsidizes screening of 12 types of congenital disabilities. As per a report published in the International Journal of Environmental Research and Public Health in July 2022, China has a high prevalence of congenital disabilities of nearly 5.6%, and it is estimated that nearly 800,000 to 1,200,000 people children every year are found with malformations, which includes more than 2,500,000 malformation cases.
For this, certain chromosomal diagnostic arrays are being used to test individuals for unexplained developmental delay/intellectual disability (DD/ID), autism spectrum disorders (ASDs), or multiple congenital anomalies (MCA).
Table of contents
9 chapters · 80 sections · 109 pages · click to expandSegmental analysis
| Segment | Largest share (2024) | Fastest growth (2024–2031) |
|---|---|---|
| By Product | Consumables | Consumables |
| By Application | Drug Discovery & Development | Research applications |
| By End User | Pharmaceutical and Biotechnology Companies | Contract research organizations (CROs) |
By Product
- The Consumables Segment to Account for the Largest Share of this Market in 2024
- The consumables segment is expected to account for the largest share of 62.6% of the China microarray market.
- The substantial market share of this segment is due to the increasing incidence of cancer, wide application areas of microarray technology, rising funding for genomic R&D, and growing research for personalized medicine.
- Furthermore, the consumables segment is slated to register the highest CAGR of 9.2% during the forecast period.
- The increased volume of testing for chronic diseases and the rising awareness among the general population about testing and disease awareness drive this segment's growth.
By Application
- The drug discovery & development segment is expected to account for the largest share of 51.7% of the China microarray market.
- The large market share is due to the growing public and private investments in pharma and biotech R&D and initiatives by the pharmaceutical and biotechnology companies to expand their research capabilities by opening new research centers and launches of new and innovative microarray technologies.
- Moreover, the research applications segment is expected to record the highest CAGR of 9.2% during the forecast period.
- The high sensitivity of microarray technologies, low sample volume requirements, and cost-effectiveness drive this segment's growth.
By End User
- The pharmaceutical and biotechnology companies segment is expected to account for the largest share of the China microarray market.
- This segment's substantial market share is due to high pharmaceutical R&D expenditure, rising demand for new drug discovery & development, increasing funding, grants, and investments for genomic research, and growing focus on increasing overall productivity.
- The rising demand for drug discovery coupled with the rising R&D expenditure will increase the demand for techniques such as microarray technology that offer accurate results and provide better and vast information.
- Moreover, the contract research organizations (CROs) segment is projected to record the highest CAGR during the forecast period.
Competitive landscape
- Sino Biological, Inc. · China
- CapitalBio Technology Co., Ltd. · China
- Arrayit Corporation (U.S.)
- Thermo Fisher Scientific, Inc. (U.S.)
- Illumina, Inc. (U.S.)
- Revvity, Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Merck KGaA · Germany
- Qiagen N.V. · Netherlands
- RayBiotech Life, Inc. (U.S.)
Frequently asked questions
The China microarray market size is estimated at USD 622.5 million in 2026.
Cite this report
Meticulous Research. (2026). China Microarray Market - Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-1321). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/china-microarray-market-6004